On September 14th, the FDA approved Ajovy for migraine prevention, and now Emgality has been approved as well. These are the 2nd and 3rd monoclonal antibodies to be approved specifically for the prevention of migraine. A very exciting time for migraine research, migraine treatment, for migraine patients and care providers!

While each of these treatments, Aimovig, Ajovy, and Emgality, all have their differences, they have some similarities too. They are all intended for migraine prevention, they are all monthly injections, or in the case of Ajovy, there is a once every 3 month protocol that was approved as well. Also, tolerability is very good across all of these treatments.

One of these might be the right medication for you. Make an appointment to see a headache specialist to talk about migraine treatment options.